SEC INSIDER TRANSACTIONS

BECTON DICKINSON & CO (BDX) Insider Transactions

Explore official ownership filings, with every record linked to its source.

Reported data · not live

BDX · BECTON DICKINSON & CO

Filing window SEC codes (comma separated) Security type Order

More transaction filters

Roles: director,officer,ten_percent_owner,otherOwner nameOfficer titleOwnership: D, I, unknownoriginal or amendedTransaction fromTransaction throughFiled fromFiled throughMinimum quantityMaximum quantityMinimum priceMaximum priceMinimum calculated valueMaximum calculated valueResults per page (1–100)

OR within codes/roles; AND between categories. Roles apply to buyers and sellers. Owner predicates match the same owner. Missing values fail numeric/date filters. Value is quantity × reported price for non-derivative rows only; derivative values are unknown. Amendments stay separate; joint owners do not duplicate rows.

Reset filters

Active filters: days=6m

Stale snapshot · Covered: filings 2026-05-14 to 2026-11-13 · 22 filings · fetched 2026-11-13T16:39:22Z

Recent reported activity

0purchase rows on this page

10sale rows on this page

30matching filing rows

Purchases and sales count original non-derivative P and S rows. Awards, gifts, exercises, derivatives and amendments are shown separately and are not described as market purchases.

Transaction / filed	Reporting owner(s)	Code / security	Quantity	Price as filed	Ownership	Source
2026-11-06Filed 2026-11-10	Byington Carrie LDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The securities convert to common stock on a one-for-one basis. F2 The securities are distributed following termination of the reporting person's service as a director, or on the date or dates specified by the reporting person. F3 Includes rights acquired through dividend investment since the last report filed by the reporting person. References: F1, F2, F3	A Award / grantRights to Common Stock Under 1996 Directors Deferral Plan · Derivative	79A	197.88	Direct	Form 4 ↗0001628280-26-072778
2026-11-06Filed 2026-11-10	Huffines Robert LutherDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The securities convert to common stock on a one-for-one basis. F2 The securities are distributed following termination of the reporting person's service as a director, or on the date or dates specified by the reporting person. F3 Includes rights acquired through dividend investment since the last report filed by the reporting person. References: F1, F2, F3	A Award / grantRights to Common Stock Under BD Deferred Compensation Plan · Derivative	158A	197.88	Direct	Form 4 ↗0001628280-26-072781
2026-11-05Filed 2026-11-09	Polen Thomas E JrDirector · Officer · Chairman, CEO and President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Award terms reflect the adjustments made in connection with the embecta spinoff and the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. F2 The stock appreciation rights vest in four annual installments beginning November 26, 2019. The reported transactions were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 2, 2026. References: F1, F2	M Exercise / conversionStock Appreciation Rights · Derivative	20,239D	0	Direct	Form 4 ↗0001628280-26-072360
2026-11-05Filed 2026-11-09	Polen Thomas E JrDirector · Officer · Chairman, CEO and President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Award terms reflect the adjustments made in connection with the embecta spinoff and the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. F2 The stock appreciation rights vest in four annual installments beginning November 26, 2019. The reported transactions were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 2, 2026. References:	S Sale (market/private)Common Stock · Non-derivative	2,993D	210	Direct	Form 4 ↗0001628280-26-072360
2026-11-05Filed 2026-11-09	Polen Thomas E JrDirector · Officer · Chairman, CEO and President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Award terms reflect the adjustments made in connection with the embecta spinoff and the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. F2 The stock appreciation rights vest in four annual installments beginning November 26, 2019. The reported transactions were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 2, 2026. References:	D Other reported codeCommon Stock · Non-derivative	17,246D	210	Direct	Form 4 ↗0001628280-26-072360
2026-11-05Filed 2026-11-09	Polen Thomas E JrDirector · Officer · Chairman, CEO and President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Award terms reflect the adjustments made in connection with the embecta spinoff and the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. F2 The stock appreciation rights vest in four annual installments beginning November 26, 2019. The reported transactions were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 2, 2026. References:	M Exercise / conversionCommon Stock · Non-derivative	20,239A	178.94	Direct	Form 4 ↗0001628280-26-072360
2026-10-26Filed 2026-10-27	Feld MichaelOfficer · EVP, Chief Revenue Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. This reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 27, 2026. References:	S Sale (market/private)Common Stock · Non-derivative	76D	198.13	Direct	Form 4 ↗0001628280-26-067525
2026-09-28Filed 2026-09-29	Feld MichaelOfficer · EVP, Chief Revenue Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. This reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 27, 2026. References:	S Sale (market/private)Common Stock · Non-derivative	76D	183.7	Direct	Form 4 ↗0001628280-26-063882
2026-09-02Filed 2026-09-03	Roque VitorOfficer · EVP & Chief Financial Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares withheld for payment of withholding taxes in connection with vesting of previously reported restricted stock unit awards References: F1	F WithholdingCommon Stock · Non-derivative	190D	0	Direct	Form 4 ↗0001628280-26-060580
2026-08-26Filed 2026-08-27	Feld MichaelOfficer · EVP, Chief Revenue Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. This reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 27, 2026. References:	S Sale (market/private)Common Stock · Non-derivative	165D	188.49	Direct	Form 4 ↗0001628280-26-059269
2026-08-20Filed 2026-08-24	Feld MichaelOfficer · EVP, Chief Revenue Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents shares withheld for payment of withholding taxes in connection with vesting of previously reported restricted stock unit awards References: F1	F WithholdingCommon Stock · Non-derivative	1,049D	0	Direct	Form 4 ↗0001628280-26-058647
2026-08-13Filed 2026-08-14	Polen Thomas E JrDirector · Officer · Chairman, CEO and President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Award terms reflect the adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. F2 The stock appreciation rights vested in four annual installments beginning November 26, 2018. The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 2, 2026. References: F1, F2	M Exercise / conversionStock Appreciation Rights · Derivative	43,278D	0	Direct	Form 4 ↗0001628280-26-057166
2026-08-13Filed 2026-08-14	Polen Thomas E JrDirector · Officer · Chairman, CEO and President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Award terms reflect the adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. F2 The stock appreciation rights vested in four annual installments beginning November 26, 2018. The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 2, 2026. References:	S Sale (market/private)Common Stock · Non-derivative	4,152D	185	Direct	Form 4 ↗0001628280-26-057166
2026-08-13Filed 2026-08-14	Polen Thomas E JrDirector · Officer · Chairman, CEO and President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Award terms reflect the adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. F2 The stock appreciation rights vested in four annual installments beginning November 26, 2018. The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 2, 2026. References:	D Other reported codeCommon Stock · Non-derivative	39,126D	185	Direct	Form 4 ↗0001628280-26-057166
2026-08-13Filed 2026-08-14	Polen Thomas E JrDirector · Officer · Chairman, CEO and President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Award terms reflect the adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. F2 The stock appreciation rights vested in four annual installments beginning November 26, 2018. The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 2, 2026. References:	M Exercise / conversionCommon Stock · Non-derivative	43,278A	167.25	Direct	Form 4 ↗0001628280-26-057166
2026-08-11Filed 2026-08-12	Goette RolandOfficer · EVP and President, EMEA Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Securities sold were common stock acquired through the Becton, Dickinson and Company Global Share Investment Program (the "GSIP"). F2 Holdings reflect the addition of dividends the reporting person received as part of the equity adjustment made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. F3 Represents shares of common stock held under the Becton, Dickinson and Company Global Share Investment Program (the "GSIP"). The information presented for the GSIP is as of August 3, 2026. References: F1, F2	S Sale (market/private)Common Stock · Non-derivative	2,438D	180.84	Direct	Form 4 ↗0001628280-26-056366
2026-08-06Filed 2026-08-06	Huffines Robert LutherDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The securities convert to common stock on a one-for-one basis. F2 The securities are distributed following termination of the reporting person's service as a director, or on the date or dates specified by the reporting person. F3 Includes rights acquired through dividend investment since the last report filed by the reporting person. References: F1, F2, F3	A Award / grantRights to Common Stock Under BD Deferred Compensation Plan · Derivative	189A	165.62	Direct	Form 4 ↗0001628280-26-054422
2026-08-06Filed 2026-08-06	Byington Carrie LDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The securities convert to common stock on a one-for-one basis. F2 The securities are distributed following termination of the reporting person's service as a director, or on the date or dates specified by the reporting person. F3 Includes rights acquired through dividend investment since the last report filed by the reporting person. References: F1, F2, F3	A Award / grantRights to Common Stock Under BD Deferred Compensation Plan · Derivative	94A	165.62	Direct	Form 4 ↗0001628280-26-054418
2026-07-27Filed 2026-07-28	Feld MichaelOfficer · EVP, Chief Revenue Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. This reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 7, 2025. References:	S Sale (market/private)Common Stock · Non-derivative	75D	157.13	Direct	Form 4 ↗0001628280-26-049989
2026-07-02Filed 2026-07-06	Muhsin BilalOfficer · EVP & President Connected Care Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. F2 Direct holdings reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. to the number of shares underlying previously reported and unvested time-vested restricted stock units held by the reporting person. F3 Represents shares withheld for payment of withholding taxes in connection with the vesting of restricted stock units previously reported on Table I. References: F3	F WithholdingCommon Stock · Non-derivative	1,935D	0	Direct	Form 4 ↗0001628280-26-047193
2026-07-01Filed 2026-07-06	Muhsin BilalOfficer · EVP & President Connected Care Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. F2 Direct holdings reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. to the number of shares underlying previously reported and unvested time-vested restricted stock units held by the reporting person. F3 Represents shares withheld for payment of withholding taxes in connection with the vesting of restricted stock units previously reported on Table I. References: F1, F2	A Award / grantCommon Stock · Non-derivative	14,342A	0	Direct	Form 4 ↗0001628280-26-047193
2026-06-26Filed 2026-06-26	Feld MichaelOfficer · EVP, Chief Revenue Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. This reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 7, 2025. References:	S Sale (market/private)Common Stock · Non-derivative	75D	152.8	Direct	Form 4 ↗0001628280-26-045864
2026-06-24Filed 2026-06-25	Garrison Michael DavidOfficer · EVP & Pres Med.Essntl&BioPharm Filing context Reported filing row; may be amended. Do not sum filings blindly. The reported transactions were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 18, 2026. References:	S Sale (market/private)Common Stock · Non-derivative	1,100D	145.66	Direct	Form 4 ↗0001628280-26-045374
2026-06-10Filed 2026-06-11	Garrison Michael DavidOfficer · EVP & Pres Med.Essntl&BioPharm Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Direct holdings reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. to the number of shares underlying previously reported and unvested time-vested restricted stock units held by the reporting person. The reported transactions were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 18, 2026. References: F1	S Sale (market/private)Common Stock · Non-derivative	1,100D	151.48	Direct	Form 4 ↗0001628280-26-042571
2026-06-01Filed 2026-06-03	Polen Thomas E JrDirector · Officer · Chairman, CEO and President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $145.21 through $147.49. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. F2 Direct holdings reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. to the number of shares underlying previously reported and unvested time-vested restricted stock units held by the reporting person. F3 Award terms reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. F4 The stock appreciation rights vested in four annual installments beginning November 26, 2017. The reported transactions were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 2, 2026. References: F3, F4	M Exercise / conversionStock Appreciation Rights · Derivative	20,209D	0	Direct	Form 4 ↗0001628280-26-040095

Imported instruments only. Joint owners do not multiply transactions. Amendments are separate filing rows, not additional trades. No aggregate trade totals are implied.